The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s intravenous immunoglobulin market report forecasts the intravenous immunoglobulin market size to grow to $17.95 Billion by 2027, with a CAGR (compound annual growth rate) of almost 7%.

Learn More On The Intravenous Immunoglobulin Market Report 2023 – https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Intravenous Immunoglobulin Market Size Forecast
The global intravenous immunoglobulin market is expected to grow from $12.86 billion in 2022 to $13.75 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intravenous immunoglobulin market size is expected to grow to $17.95 billion in 2027 at a CAGR of 6.9%.

North America held the largest intravenous immunoglobulin market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Intravenous Immunoglobulin Market Driver ­– Increase In The Geriatric Population
For instance, in 2021, according to the Elderly in India 2021 report by the National Statistical Office (NSO), a statistics wing of the Ministry of Statistics and Programme Implementation of the government of India, in 2021, 138 million elderly people were there in India and the number is expected to rise to 194 million by 2031. Additionally, according to the World Health Organization (WHO), a specialized agency of the United Nations, by 2030, 1 in 6 people in the world will be 60 years or older and the total number of people over 60 years will increase to 1.4 billion by 2030 increasing from 1 billion in 2020. As a result, the increasing geriatric population will drive the intravenous immunoglobulin market forward.

Request for A Sample Of The Global Intravenous Immunoglobulin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Key Intravenous Immunoglobulin Market Trend – Product Innovation
Major companies in the market are focusing on innovating new products such as human plasma-derived intravenous immunoglobulin (IVIg) for the treatment of rare diseases and sustaining their position in the market. For instance, in June 2021, Octapharma, a Swiss pharmaceutical company, announced that its new product ‘Octagam 10%’, a human plasma-derived intravenous immunoglobulin (IVIg) was granted approval by the European Union (EU) as immunotherapy for adults with dermatomyositis, and national approval by Germany for the same indication. Octagam 10% is the first therapy to be approved for dermatomyositis in the EU and indicated for adults with active dermatomyositis treated with immunosuppressive drugs. This innovative product will help improve the lives of people with dermatomyositis, which is a rare, idiopathic autoimmune disorder.

Intravenous Immunoglobulin Market Segment
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Intravenous Immunoglobulin Market Major Players and Strategies
Major players in the intravenous immunoglobulin market are Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols SA, Kedrion SpA, Shanghai RAAS Blood Products Co Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products BV, Prothya Biosolutions BV, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd., and Pfizer Inc.

In March 2021, Grifols SA, a Spanish pharmaceutical and chemical manufacturer acquired GigaGen Inc for $115 million. The acquisition was completed in two stages; in the first stage, Grifols bought a 44% stake for $35 million and in the second stage, it bought the remaining 56% share for $80 million. The acquisition is in line with Grifols’ R+D+I (research, development, and innovation) strategy to boost innovation and perform research that compliments its core operations. GigaGen is a US-based biotechnology company specializing in the development and discovery of recombinant biotherapeutic medicines.

The Intravenous Immunoglobulin Global Market Report 2023 covers regional data on intravenous immunoglobulin market size, intravenous immunoglobulin market trends and drivers, opportunities, strategies, and intravenous immunoglobulin market competitor analysis. The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Intravenous immunoglobulin refers to a therapy used for the treatment of immunodeficient people. It is administered in the form of intravenous infusion. Infusion liquid is made from immunoglobulins collected from healthy individuals and purified to eliminate any blood-borne infection or impurity.

View More Reports Related To The Intravenous Immunoglobulin Market –
Immunoglobulins Global Market Report 2023
Immunofluorescence Assay Global Market Report 2023
Immunosuppressants Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: